Results 31 to 40 of about 22,180 (202)

Cost-Effectiveness Analysis of Long-acting Injectable Once-monthly of Aripiprazole Compared with Long-acting Injectable Once-monthly Paliperidone Palmitate for the Treatment of Stable Schizophrenia Patients in Thailand

Siriraj Medical Journal, 2023
Objective: Long-acting injectable (LAI)-aripiprazole and LAI-paliperidone palmitate are both second-generation antipsychotics that have been introduced to increase drug compliance in patients.
Piyanut Ueapanjasin, Wiwat Thavornwattanayong, Jadesada Lertsirimunkong, Kamolpat Chaiyakittisopon   +3 more
doaj  

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

Clinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples, Shayna R. Killam, Karen E. Brown, Rachel Dalton, Elizabeth Sather, Qiang Chen, Joshua Loveland, Corbin Schwanke, Abdallah F. Elias, Kristin L. Bigos, Erica L. Woodahl   +10 more
wiley   +1 more source

Aripiprazole and lactation failure: The importance of shared decision making. A case report

Case Reports in Women's Health, 2021
Bipolar disorder is a chronic and severe psychiatric illness affecting many patients during their childbearing years. Bipolar disorder is often managed with aripiprazole, a generally well tolerated second-generation antipsychotic medication.
Ariana Komaroff
doaj   +1 more source

Trends in the Use of Atypical Antipsychotics Among Children and Adolescents With Bipolar Spectrum Disorders in Korea. [PDF]

Bipolar Disord
ABSTRACT Introduction Atypical antipsychotics (AAPs) are increasingly prescribed for bipolar spectrum disorders in children and adolescents. This study aimed to investigate the prevalence and trends of AAP prescriptions among Korean children and adolescents with bipolar spectrum disorders.
Park KJ, Kim YJ, Jung E, Kim JY, Kim HW.
europepmc   +2 more sources

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Aripiprazole

Reactions Weekly, 2006
europepmc   +5 more sources

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Aripiprazole induced severe parkinsonism: a case report

Neuropsychiatric Investigation, 2015
Aripiprazole, a D2 and 5-HT1A receptor partial agonist and 5-HT2A receptor antagonist, is an atypical antipsychotic. Previous studies indicated that the rate of extrapyramidal symptoms caused by aripiprazole is very close to that of placebo.
İkbal İNANLI, Ali Metehan ÇALIŞKAN, Ayşe KÜRKCÜ, İbrahim EREN   +3 more
doaj   +1 more source

Exploring Cerumen as an Alternative Matrix for Drug Detection and Quantification: Method Development and Application in Clinical Samples

Drug Testing and Analysis, EarlyView.
An LC–MS/MS method was developed for the detection of 33 psychoactive medications in cerumen (earwax) and applied to the samples of 60 psychiatric inpatient volunteers. The findings highlighted the utility of cerumen as an innovative biospecimen in clinical toxicological analysis.
Dimitrios Phaedon Kevrekidis, Helen G. Gika, Georgios Panagiotoglou, Eleni Parlapani, Pavlos Pavlidis, Nikolaos Raikos   +5 more
wiley   +1 more source

Asymmetric tremor due to possible valproic acid-aripiprazole interaction in a child with severe intellectual disability (eng)

Klinik Psikiyatri Dergisi, 2021
Intellectual disability is a neurodevelopmental disorder common. Treatment of behavioral problems in this group; antipsychotic drugs, mood stabilizers drugs are often used.
Enes Sarıgedik, Neslihan Kara, Cigdem Yektas   +2 more
doaj   +1 more source